We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations New real-world evidence shows Beyfortus (nirsevimab) substantially reduced RSV lower...
Communiqué de presse : Assemblée Générale Annuelle du 30 avril 2024 Assemblée Générale Annuelle du 30 avril 2024 Approbation des comptes sociaux et des comptes consolidés de l’exercice...
Press Release: Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance Paris...
Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia Pivotal...
New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis Data support frexalimab as a potential first-in-class, high-efficacy, non-lymphocyte...
Communiqué de presse : De nouveaux résultats de phase II à 48 semaines relatifs au frexalimab confortent le potentiel d'efficacité élevée et durable dans le traitement de la sclérose en...
Sanofi: Informations relatives au nombre de droits de vote et d'actions - Mars 2024 Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8...
Sanofi - AGM 30.04.2024 - Mise à disposition des documents préparatoires ASSEMBLEE GENERALE MIXTE DU 30 AVRIL 2024 MODALITES DE MISE A DISPOSITION OU DE CONSULTATION DES DOCUMENTS...
Communiqué de presse : Mise en ligne du document «Q1 2024 Memorandum for modelling purposes» Mise en ligne du document «Q1 2024 Memorandum for modelling purposes» Paris, France, le 22 mars...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.08 | -0.0875465090829 | 91.38 | 94.03 | 89.63 | 1685219 | 92.07705928 | DE |
4 | 3.5 | 3.98633257403 | 87.8 | 94.03 | 85.07 | 1515508 | 88.78862534 | DE |
12 | 4.6 | 5.30565167243 | 86.7 | 94.03 | 84.93 | 1402232 | 88.36363425 | DE |
26 | 4.4 | 5.06329113924 | 86.9 | 96.5 | 82.86 | 1448793 | 88.4668883 | DE |
52 | -5.83 | -6.00226500566 | 97.13 | 104.32 | 80.6 | 1444206 | 92.85957011 | DE |
156 | 3.91 | 4.47419613228 | 87.39 | 106.66 | 76.45 | 1803072 | 91.07286959 | DE |
260 | 13.5 | 17.35218509 | 77.8 | 106.66 | 67.65 | 2049813 | 87.34742052 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions